Nocturnal enteral nutrition is therapeutic for growth failure in Fanconi-Bickel syndrome.
Fanconi-Bickel syndrome
glucose transporter-2
glycogen storage disease type XI
nocturnal enteral nutrition
proximal renal tubular dysfunction
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
27
09
2019
revised:
04
12
2019
accepted:
06
12
2019
pubmed:
10
12
2019
medline:
24
8
2021
entrez:
10
12
2019
Statut:
ppublish
Résumé
Fanconi-Bickel syndrome (FBS) is a rare autosomal recessive disorder characterised by impaired glucose liver homeostasis and proximal renal tubular dysfunction. It is caused by pathogenic variants in SLC2A2 coding for the glucose transporter GLUT2. Main clinical features include hepatomegaly, fasting hypoglycaemia, postprandial hyperglycaemia, Fanconi-type tubulopathy occasionally with rickets, and a severe growth disorder. While treatment for renal tubular dysfunction is well established, data regarding optimal nutritional therapy are scarce. Similarly, detailed clinical evaluation of treated FBS patients is lacking. These unmet needs were an incentive to conduct the present pilot study. We present clinical findings, laboratory parameters and molecular genetic data on 11 FBS patients with emphasis on clinical outcome under various nutritional interventions. At diagnosis, the patients' phenotypic severity could be classified into two categories: a first group with severe growth failure and rickets, and a second group with milder signs and symptoms. Three patients were diagnosed early and treated because of family history. All patients exhibited massive glucosuria at diagnosis and some in both groups had fasting hypoglycaemic episodes. Growth retardation improved drastically in all five patients treated by intensive nutritional intervention (nocturnal enteral nutrition) and uncooked cornstarch with final growth parameters in the normal range. The four severely affected patients who were treated with uncooked cornstarch alone did not catch up growth. All patients received electrolytes and l-carnitine supplementation to compensate for the tubulopathy. This is one of the largest series of FBS on therapeutic management with evidence that nocturnal enteral nutrition rescues growth failure.
Substances chimiques
Glucose Transporter Type 2
0
SLC2A2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
540-548Informations de copyright
© 2019 SSIEM.
Références
Fanconi G, Bickel H. Chronic aminoaciduria (amino acid diabetes or nephrotic-glucosuric dwarfism) in glycogen storage and cystine disease. Helv Paediatr Acta. 1949;4:359-396.
Santer R, Schneppenheim R, Suter D, Schaub J, Steinmann B. Fanconi-Bickel syndrome-the original patient and his natural history, historical steps leading to the primary defect, and a review of the literature. Eur J Pediatr. 1998;157:783-797.
Dweikat IM, Alawneh IS, Bahar SF, Sultan MI. Fanconi-Bickel syndrome in two Palestinian children: marked phenotypic variability with identical mutation. BMC Res Notes. 2016;9:387.
Fridman E, Zeharia A, Markus-Eidlitz T, Haimi Cohen Y. Phenotypic variability in patients with fanconi-bickel syndrome with identical mutations. JIMD Rep. 2015;15:95-104.
Khandelwal P, Sinha A, Jain V, Houghton J, Hari P, Bagga A. Fanconi syndrome and neonatal diabetes: phenotypic heterogeneity in patients with GLUT2 defects. CEN Case Rep. 2018;7:1-4.
Grünert SC, Schwab KO, Pohl M, Sass JO, Santer R. Fanconi-Bickel syndrome: GLUT2 mutations associated with a mild phenotype. Mol Genet Metab. 2012;105:433-437.
Santer R, Schneppenheim R, Dombrowski A, Götze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17:324-326.
Lee PJ, Van't Hoff WG, Leonard JV. Catch-up growth in Fanconi-Bickel syndrome with uncooked cornstarch. J Inherit Metab Dis. 1995;18:153-156.
Dixon, M., MacDonald, A., Stafford, J., White, F., & Portnoi, P. (2014). 18 Disorders of Carbohydrate Metabolism.In:Shaw V(ed)Clin Paediatr,4th edn.Oxford Boston Wiley-Blackwell
Bali DS, Chen Y-T, Austin S, Goldstein JL. Glycogen storage disease type I. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. University of. Washington, Seattle: Seattle (WA); 1993.
Santer R, Groth S, Kinner M, et al. The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet. 2002;110:21-29.
Shi PP, Wang M, Dou WJ. [Fanconi-Bickel syndrome with SLC2A2 gene mutation in a child]. Zhonghua Er Ke Za Zhi Chin. J Pediatr. 2018;56:65-66.
Haffner D, Weinfurth A, Manz F, et al. Long-term outcome of paediatric patients with hereditary tubular disorders. Nephron. 1999;83:250-260.
Haffner D, Weinfurth A, Seidel C, et al. Body growth in primary de Toni-Debré-Fanconi syndrome. Pediatr Nephrol Berl Ger. 1997;11:40-45.
Manz F, Bickel H, Brodehl J, et al. Fanconi-Bickel syndrome. Pediatr Nephrol Berl Ger. 1987;1:509-518.
Shikhman AR, Brinson DC, Lotz MK. Distinct pathways regulate facilitated glucose transport in human articular chondrocytes during anabolic and catabolic responses. Am J Physiol Endocrinol Metab. 2004;286:E980-E985.
Ohara H, Tamayama T, Maemura K, et al. Immunocytochemical demonstration of glucose transporters in epiphyseal growth plate chondrocytes of young rats in correlation with autoradiographic distribution of 2-deoxyglucose in chondrocytes of mice. Acta Histochem. 2001;103:365-378.
Mobasheri A, Vannucci SJ, Bondy CA, et al. Glucose transport and metabolism in chondrocytes: a key to understanding chondrogenesis, skeletal development and cartilage degradation in osteoarthritis. Histol Histopathol. 2002;17:1239-1267.
Rampini S, Fanconi A, Illig R, Prader A. Effect of hydrochlorothiazide on proximal renal tubular acidosis in a patient with idiopathic “de toni-debré-fanconi syndrome.”. Helv Paediatr Acta. 1968;23:13-21.